Actively Recruiting
Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing
Led by Centre Hospitalier Universitaire de la Guadeloupe · Updated on 2025-11-26
100
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
: Encephalitis or myelitis is defined as the inflammatory or infectious involvement of the cerebral parenchyma or spinal cord. When an infectious origin is suspected, the germ is not always identified. Next-generation sequencing could be used to correct an etiological diagnosis of these severe conditions in Guadeloupe. The rate of cases for which the infectious agent is not identified encourages continued diagnostic efforts, with the objective of identifying new pathogens or emerging pathogens, some of which may be more specific in the tropics.
CONDITIONS
Official Title
Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is at least 28 days old
- Acute onset of symptoms lasting more than 24 hours
- For encephalitis: major symptom such as altered consciousness, memory disorder, lethargy, behavioral changes, irritability, confusion, or disorientation
- For encephalitis: at least two minor symptoms including fever above 38 °C, new focal neurological deficit, epileptic crisis, abnormal cerebrospinal fluid, seizures not related to previous epilepsy, or brain imaging/EEG suggestive of encephalitis
- For myelitis: medullary focal abnormality causing motor, sensory, or autonomic symptoms
- For myelitis: contrast enhancement on spinal MRI and/or abnormal cerebrospinal fluid
- For myelitis: symptom progression from nadir to maximum in less than 4 weeks
- No alternative diagnosis such as intoxication or metabolic encephalopathy
- Affiliated with or benefiting from a social security scheme
- Provided free, informed, written, and signed consent by patient or legal representative before inclusion
You will not qualify if you...
- Primary central nervous system vasculitis or documented autoimmune impairment
- Cerebral thrombophlebitis without encephalitis
- Meningitis without signs of brain involvement
- Pyogenic brain abscess
- Cerebral or spinal abscess
- Tumor or hematological disease of the central nervous system
- Toxic or metabolic encephalopathy
- Transverse myelitis caused by vascular or traumatic origin
- Known chronic infection with HTLV virus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Universitaire de la Guadeloupe
Pointe-à-Pitre, Guadeloupe, Guadeloupe, 97159
Actively Recruiting
Research Team
V
Val"érie HAMONY-SOTER
CONTACT
E
Eunice NUBRET
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here